A Phase II Single-arm Study of AMG 386 in Combination With Docetaxel for Advanced Urothelial Carcinoma After Failure of a Platinum-containing Regimen
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 17 Jun 2014
Price : $35 *
At a glance
- Drugs Trebananib (Primary) ; Docetaxel
- Indications Urogenital cancer
- Focus Therapeutic Use
- 28 Apr 2014 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 24 Dec 2013 Planned initiation date changed from 1 Dec 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.
- 31 Jul 2013 New trial record